Guidance for Restarting Inflammatory Bowel Disease Therapy in Patients Who Withheld Immunosuppressant Medications During COVID-19 by Siegel, C.A. et al.
Guidance for Restarting Inflammatory Bowel 
Disease Therapy in Patients Who Withheld 
Immunosuppressant Medications During 
COVID-19
Corey A. Siegel,a Britt Christensen,b, Asher Kornbluth,c Joel R. Rosh,d 
Michael D.  Kappelman,e Ryan C. Ungaro,c Douglas Forsyth Johnson,f 
Scott Chapman,g David A.  Wohl,h Gerassimos J. Mantzarisi; for the 
International Organization for the Study of Inflammatory Bowel 
Diseases [IOIBD]
aSection of Gastroenterology and Hepatology, Dartmouth-Hitchcock IBD Center, Lebanon, NH, USA bGastroenterology 
Department, Royal Melbourne Hospital, Melbourne, VIC, Australia cHenry D. Janowitz Division of Gastroenterology, 
Icahn School of Medicine at Mount Sinai, New York, NY, USA dDivision of Pediatric Gastroenterology, Goryeb 
Children’s Hospital, Morristown, NJ, USA eDepartment of Pediatrics, University of North Carolina at Chapel Hill, 
Chapel Hill, NC, USA fDepartments of Infectious Diseases and Internal Medicine, Royal Melbourne Hospital, 
Melbourne, VIC, Australia gDepartment of Infectious Diseases, St Vincent’s Hospital, Sydney, NSW, Australia 
hDivision of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA iDepartment of 
Gastroenterology, Evaggelismos-Ophthalmiatreion Athinon-Polykliniki GHA, Athens, Greece
Corresponding author: Dr Corey A. Siegel, MD, MS, Inflammatory Bowel Disease Center, Section of Gastroenterology and 
Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA. Tel.: [603] 650 8101; email: corey.a.siegel@ 
hitchcock.org
Abstract 
Patients with inflammatory bowel diseases [IBD] are frequently treated with immunosuppressant 
medications. During the coronavirus disease 2019 [COVID-19] pandemic, recommendations for IBD 
management have included that patients should stay on their immunosuppressant medications 
if they are not infected with the severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], 
but to temporarily hold these medications if symptomatic with COVID-19 or asymptomatic but 
have tested positive for SARS-CoV-2. As more IBD patients are infected globally, it is important to 
also understand how to manage IBD medications during convalescence while an individual with 
IBD is recovering from COVID-19. In this review, we address the differences between a test-based 
versus a symptoms-based strategy as related to COVID-19, and offer recommendations on when 
it is appropriate to consider restarting IBD therapy in patients testing positive for SARS-CoV-2 or 
with clinical symptoms consistent with COVID-19. In general, we recommend a symptoms-based 
approach, due to the current lack of confidence in the accuracy of available testing and the clinical 
significance of prolonged detection of virus via molecular testing. 
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1. Introduction
Many patients with inflammatory bowel disease [IBD] require medi-
cations that affect the immune system. Although effective in treating 
the inflammation associated with Crohn’s disease [CD] and ulcera-
tive colitis [UC], these medications can also increase the risk and 
severity of infection.1 As the severe acute respiratory syndrome 
coronavirus 2 [SARS-CoV-2], causing coronavirus disease 2019 
[COVID-19], spread from late 2019 to early 2020 and became pan-
demic, many patients with IBD and their providers were forced to 
consider how to manage IBD given the potential effect of immuno-
suppression on the risk of developing COVID-19 and its associated 
complications.
A number of consensus statements provide initial guidance on 
how to manage IBD patients in the setting of COVID-19.2–7 Most of 
the recommendations are related to infection prevention, responding 
to patients who have a positive test for SARS-CoV-2 but who are free 
of COVID-19 symptoms, and managing those with symptomatic 
COVID-19. The general guidance states that immunosuppressant 
medications should not be stopped prophylactically in asymptom-
atic and uninfected patients, but should be withheld in those who 
either test positive for SARS-CoV-2 without symptoms or develop 
clinical COVID-19.2,5,7 As more IBD patients are infected globally, 
it is important to also understand how to manage IBD medications 
during convalescence while an individual with IBD is recovering 
from COVID-19. We aimed to review factors contributing to the de-
cision making around medication use during this time interval, and 
offer guidance on the timing of restarting IBD therapy in patients 
with IBD. Because there are currently inadequate evidence-based 
data, the following recommendations are based on a consensus of a 
group of international IBD and infectious disease experts convened 
by the International Organization for the Study of Inflammatory 
Bowel Disease [IOIBD].
2. Concepts Driving the Recommendations
2.1.  Safety of IBD medications in patients with 
COVID-19
Data are accumulating on the outcomes of patients with IBD who 
have had COVID-19. The Surveillance Epidemiology of Coronavirus 
[COVID-19] Under Research Exclusion [SECURE-IBD] database is 
a global database intended to evaluate the outcomes of IBD patients 
infected with COVID-19.8 Their composite endpoint is the propor-
tion of patients who require an admission to the intensive care unit 
[ICU], use of a ventilator, or death. From the data on close to 1000 
patients reported to date, the medication class with the highest pro-
portion of patients experiencing this endpoint is corticosteroids. The 
largest group represented in the database are patients taking anti-
tumour necrosis factor [TNF] therapy, and these patients appear to 
be at low risk of developing any of the serious outcomes. This is con-
sistent for drugs that inhibit interleukin [IL]-12/23 and anti-integrin 
molecules. The risk is a little higher with thiopurines, janus kinase 
[JAK] inhibitors and patients on combination therapy with an anti-
TNF and a thiopurine. 
Regional and individual hospital reports from hot spots such as 
Italy9 and New York City10 find a similar absence of an association 
between COVID-19 disease severity and IBD therapeutics, and the 
paediatric experience has also been reassuring.6 Overall, other than 
corticosteroids, it does not appear that the cornerstone therapies for 
IBD which suppress the immune system are leading to a substantial 
increase in adverse events related to COVID-19. It appears also that 
the same risk factors for the general population [ie, advanced age 
and comorbidities including hypertension, obesity, and diabetes] are 
important in the outcome of IBD patients with COVID-19.
This is reassuring, particularly in light of the fact that most of the 
immunosuppressing IBD medications have a long half-life and there-
fore are not immediately cleared after discontinuation. Nevertheless, 
as is standard with other serious infections, recommendations are to 
hold these treatments until a patient recovers and is considered to 
be in the convalescent stage.11 Therefore, guidance on the timing of 
when to recommence these medical therapies is the next important 
question for the clinician. 
2.2.  Ability of testing to identify those with active 
SARS-CoV-2 infection
Sampling of the nasopharynx for SARS-CoV-2 RNA polymerase 
chain reaction [PCR] is the clinical gold standard for the diagnosis 
of COVID-19. Whereas the loss of detectable viral RNA coupled 
with clinical recovery would be a reasonable indicator for the safe 
re-start of IBD therapy, numerous studies have demonstrated per-
sistent RNA detection in nasopharyngeal [NP] and oropharyngeal 
[OP] swabs, as well as saliva, for 28 days or more in a substantial 
proportion of patients without IBD.12 Whether the RNA detected 
represents viable virus is unknown.13,14 Reports of prolonged shed-
ding of SARS-CoV-2 RNA has also been noted in immunocomprom-
ised patients and animals with other coronaviruses.15,16 In contrast, 
it is known that the NP swab for SARS-CoV-2 RNA detection can 
yield false-negative results, possibly due to sampling error or the 
shift of the virus from the upper to the lower airway during disease 
progression. Therefore, reliance on NP swabs alone to guide the re-
start of IBD medication is not recommended. 
Serological [antibody] testing also has significant limita-
tions. Antibodies to SARS-CoV-2 become reliably detectable 14 
or more days after symptom onset; earlier in the course of infec-
tion, serological testing is more likely to be negative. There is also 
considerable variability in the performance of SARS-CoV-2 sero-
logical assays, including those that have received Emergency Use 
Authorization [EUA] from the US Food and Drug Administration 
[FDA]. The Infectious Diseases Society of America [IDSA] notes that 
false-negatives are an issue, especially when the prevalence of true 
previous infections is less than 5%. False-positives are also possible 
and can be misleading due to potential cross-reactivity with other 
common cold coronaviruses.17 Importantly, there is no evidence to 
date demonstrating that SARS-CoV-2 seropositivity protects against 
re-infection or is durable. The IDSA concludes that at the current 
time, antibody testing may be helpful to measure exposure preva-
lence at the population level, but has less utility in individual patient 
assessments. In the future, such testing may have a role in evaluating 
individual immunity. 
2.3.  Test- and non test-based approaches for 
determining transmission risk
Although the issues of when to discontinue infection control meas-
ures and return an infected health care provider to work are distinct 
from that of the re-initiation of IBD medications, there are a number 
of shared considerations. In issuing guidance for both situations, the 
Centers of Disease Control and Prevention [CDC] have offered a test-
based and a symptoms-based approach.14,18 The test-based approach 
calls for resolution of fever and symptoms plus a pair of consecutive re-
spiratory specimens with undetectable SARS-CoV-2 RNA results. The 
symptom-based strategy uses times from symptoms onset [≥10 days] 
and improvement including resolution of fever without antipyretics [≥3 
days] as criteria. This strategy reflects the low likelihood of transmis-
sion from clinically recovering individuals over time. 
The approach to determining return to work and discontinuation 
of transmission-based precautions for persons with COVID-19 can 
inform decision making regarding the timing of re-initiation of IBD 
medications during COVID-19 convalescence, as these situations 
share a primary concern for the presence of viable virus.
3. Recommendations
These recommendations take into consideration what is known about 
the safety of IBD therapies with COVID-19 and other viral infections, 
the limitations of current testing modalities, and practical considerations 
focused on getting patients back on the medications they need to control 
their IBD while reducing the risk of a flare or the development of antidrug 
antibodies. A ‘test-based’ strategy may be required in some scenarios; 
however, for most patients, we recommend a ‘symptoms-based strategy’. 
3.1.  Symptoms-based strategy
For patients with IBD who have had their immunosuppressant 
therapy held due to COVID-19, the decision of when to re-start 
therapy should follow a symptoms-based strategy.
• The timing of re-starting IBD immunosuppressant therapy should
be influenced by the clinical severity of both IBD and COVID-19.
Figure 1 shows a conceptual framework for how to consider the
timing for re-starting. For those with mild COVID-19 and a his-
tory of difficult to control IBD, earlier re-start of IBD therapy may
be considered, whereas for those with more severe COVID-19 and
well-controlled IBD, a delay in IBD therapy re-start may be desired.
• For a symptom-based strategy there are several requirements that 
need to be met before resuming immunosuppressant therapy14,19
[Figure 2]:
1. at least 3 days [72 h] since recovery defined as resolution of
fever without the use of fever-reducing medications; and
2. clinically meaningful improvement in respiratory symptoms
[eg, cough, shortness of breath]; and
3. At least 10 days have passed since symptoms first appeared.
3.2.  Test-based strategy
• The above clinical parameters must be met plus two consecutive
negative NP or OP COVID-19 molecular assays (RT-PCR or nu-
cleic acid amplification test [NAAT] swab specimens) collected
≥24 h apart. 
 • In those who tested positive for SARS-CoV-2 but were
asymptomatic, medication can resume at least 10 days since
date of the first positive COVID-19 diagnostic test assuming
they have not subsequently developed symptoms since the
positive test.
3.3.  General recommendations
• When patients meet the above criteria [test-based or symptom-
based] to resume therapy, they are also considered safe to return
to a medical infusion unit to receive intravenous medications. If
patients have persistent respiratory symptoms [eg, cough] they
should ideally be in a private room with a surgical mask and pro-
viders should wear the personal protective equipment [PPE] that
is standard in their medical setting.14
• If recommencement of immunosuppressant therapy is deemed to 
be necessary on clinical grounds and a test has been performed
and is positive for SARS-CoV-2 despite meeting the clinical cri-
teria above, we recommend moving ahead with the scheduled
treatment either at home or in an infusion unit with specific in-
fection control measures in place.
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Figure 1. Conceptual clinical strategy for when to restart immunosuppressant inflammatory bowel disease [IBD] medications in the setting of resolving COVID-
19 infection.
4. Research Gaps and Next Steps
As the COVID-19 pandemic evolves, more information comes to 
light on almost a daily basis. A critical research gap exists in the 
understanding of the characteristics of the various tests available 
and how these change during the different phases of the illness. 
If we can gain confidence in the accuracy of testing [PCR and/or 
antibody testing] and the meaning of prolonged detection of RNA 
via molecular testing, this ultimately can better guide the timing of 
restarting medications. Emerging literature is beginning to charac-
terise the short-term COVID-19 related outcomes among IBD pa-
tients, but longer-term natural history studies are needed to further 
identify adverse events associated with withholding and with re-
starting therapy.
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